Genedx Holdings Corp.
A clinical genetics company, GeneDx runs DNA testing laboratories that use whole-genome and whole-exome sequencing to help doctors diagnose rare and inherited disorders, especially in children and critical-care patients. Two National Institutes of Health scientists founded the original GeneDx in 2000 in a small Maryland lab, naming it for "gene" plus "Dx," the medical shorthand for diagnosis. The firm merged with the genomics company Sema4 in 2022, and the combined business now carries the GeneDx name.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | 13GPassive | 5.8% | 1.73M | Aug 11, 2026 |
| GOLDMAN SACHS & CO. LLC | 13GPassive | 5.8% | 1.73M | Aug 11, 2026 |
| ARK Investment Management LLC | 13G/APassive | 5.33% | 1.58M | Aug 7, 2026 |
| Catherine D. Wood | 13G/APassive | 5.33% | 1.58M | Aug 7, 2026 |
| BlackRock, Inc. | 13GPassive | 5.5% | 1.62M | Jul 28, 2026 |
| Keith A. Meister | 13D/AActivist | 17.9% | 5.36M | May 22, 2026 |
| Corvex Management LP | 13D/AActivist | 16.1% | 4.78M | May 22, 2026 |
| Eli Casdin | 13D/AActivist | 13.7% | 4.10M | May 22, 2026 |
| Casdin Partners GP, LLC | 13D/AActivist | 11.9% | 3.53M | May 22, 2026 |
| Casdin Capital, LLC | 13D/AActivist | 11.8% | 3.51M | May 22, 2026 |